AGX is certainly one of the "safer" biotechs as it has pre-R & D EPS of around 3c to support the price from its other operations if Thromboview fails. Then you have huge upside if Thromboview comes off which does not appear to be priced in at all. That's not to say that if Thromboview fails that the price wouldn't get a whipping but the underlying earnings do provide some degree of safety compared to a one trick company.
I hold AGX..........
Ed.
AGX is certainly one of the "safer" biotechs as it has pre-R & D...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CT1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.949M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 33 | 26523991 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 1564360 | 5 |
View Market Depth
| Last trade - 16.12pm 27/09/2024 (20 minute delay) ? |
| CT1 (ASX) Chart |
Day chart unavailable